No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Aoti said on Wednesday that its 'Topical Wound Oxygen', or 'TWO2', therapy has gained a fast-track treatment recommendation from the National Institute for Health and Care Excellence (NICE) and added to the NHS Supply Chain's Advanced Wound Care Framework, enabling wider and faster access across the UK healthcare system.
The AIM-traded medical technology group said NICE had included topical oxygen therapy as an adjunct to standard care for diabetic foot ulcers that were not responding to treatment, following an exceptional surveillance review of its diabetic foot problems guidelines.
Aoti said the move reflected growing recognition of TWO2 therapy's clinical benefits in accelerating the healing of chronic wounds and preventing amputations.
"I am delighted that clinicians across the NHS and, most importantly, our patients, now have easier access to this innovative limb-saving therapy," said professor Michael Edmonds of King's College London.
"The diabetic foot epidemic shows no sign of abating and is forecast to consume 1% of the entire 192bn NHS budget this year.
"TWO2 therapy is an evidence-proven adjunctive treatment which has been demonstrated to more durably heal chronic wounds and that patients can apply in their home, helping to improve access to care while reducing resource utilisation and healthcare spending."
Aoti said the NICE recommendation and NHS framework listing were not expected to materially affect its financial outlook for the year.
"With TWO2 therapy now on the NHS framework and with its inclusion in the NICE treatment guidelines, patients in England have access to its sustained healing benefits, helping to reduce the burden on strained national healthcare resources while delivering substantial quality of life benefits for patients at home," commented Aoti chief executive Dr Mike Griffiths.
"Recently published health economic research has demonstrated that broad adoption of TWO2 therapy within the NHS would significantly lower overall diabetic foot care costs.
"Such continued positive decisions only further validates our clinical and value proposition supporting a positive coverage determination by CMS in the United States."
At 1338 BST, shares in Aoti were up 4.44% at 57.44p.
Reporting by Josh White for Sharecast.com.